From Vasospasm to Precision Microvascular Medicine: Rethinking the Evaluation and Management of Raynaud's Phenomenon

Abstract

Raynaud's phenomenon (RP) has long been regarded as a benign vasospastic disorder characterized by episodic digital color changes triggered by cold exposure or emotional stress. However, accumulating evidence has fundamentally changed this perception. In patients with connective tissue diseases, particularly systemic sclerosis (SSc), RP represents far more than transient vasospasm. It is often the earliest manifestation of progressive microvascular injury and serves as a window into the pathobiology of systemic vascular disease. The challenge for clinicians is no longer merely recognizing RP, but identifying which patients are at risk for irreversible vascular damage, digital ulceration, and systemic complications.

Recent advances presented at the American College of Rheumatology Convergence and reflected in the updated British Society for Rheumatology (BSR) recommendations illustrate a paradigm shift from symptom-oriented management toward precision assessment of the microcirculation. One of the most significant developments has been the increasing role of nailfold capillaroscopy. Once considered a specialized research technique, capillaroscopy is rapidly becoming an essential component of routine rheumatology practice [1]. It enables direct visualization of the microvasculature, allowing clinicians to distinguish primary RP from secondary RP associated with systemic sclerosis and other connective tissue diseases. Beyond diagnosis, capillaroscopic findings such as giant capillaries, capillary loss, abnormal angiogenesis, and microhemorrhages provide valuable prognostic information regarding disease progression and digital vascular complications. The challenge is therefore no longer whether capillaroscopy should be performed, but how it can be implemented efficiently in busy clinical settings. Technological advances are making this transition increasingly feasible. Table 1 is comparison of Nailfold Microvascular Assessment Techniques in Systemic Sclerosis. Clinical interpretation of imaging modalities. Nailfold videocapillaroscopy currently provides the most established and standardized approach for assessing SSc-associated nailfold microangiopathy. Dermatoscopy and smartphone-based imaging offer advantages in portability and accessibility, but their broader clinical application is limited by differences in image quality, acquisition protocols, and device performance. AI-assisted analysis represents a promising approach for automated recognition and quantification of capillary abnormalities; however, current evidence should be distinguished from future applications involving individual-level prediction of disease progression or vascular complications. Accordingly, these technologies should presently be viewed as complementary approaches rather than interchangeable alternatives, with their clinical utility ultimately requiring prospective validation and demonstration of improved patient outcomes (Table 2).

Conventional videocapillaroscopy remains the reference standard but requires dedicated equipment, expertise, and considerable examination time [2]. In contrast, portable dermatoscopes and smartphone-based imaging systems have emerged as practical alternatives that substantially reduce costs while improving accessibility. Although these devices currently have lower image resolution and limited quantitative capabilities, they may be sufficient for clinical screening when combined with standardized interpretation algorithms. This democratization of capillaroscopy has the potential to extend microvascular assessment beyond tertiary referral centers to community rheumatology practices. Artificial intelligence (AI) may further accelerate this transformation. Machine learning algorithms are increasingly capable of recognizing scleroderma-specific capillary patterns, identifying giant capillaries, hemorrhages, abnormal morphology, and capillary density automatically. Automated image analysis offers several advantages, including improved reproducibility, reduced observer variability, and shortened interpretation time [3]. Importantly, AI is unlikely to replace expert clinicians but rather to function as a clinical decision support tool that facilitates early identification of patients requiring specialist evaluation. As prospective validation studies mature, AI-assisted capillaroscopy may become an integral component of precision rheumatology. Equally important is the growing recognition that vascular disease should not be assessed solely through imaging. Clinical trials in systemic sclerosis have increasingly emphasized patient-reported outcomes (PROs), acknowledging that symptom burden often differs substantially from physician assessment. Raynaud's attacks affect not only pain and hand function but also emotional well-being, occupational performance, and quality of life. Instruments such as the Assessment of Systemic Sclerosis-associated Raynaud's Phenomenon (ASRAP) questionnaire represent important progress toward standardized measurement of patient experience [4]. Integrating objective capillaroscopic findings with validated PROs provides a more comprehensive understanding of disease activity and therapeutic response than either measure alone. Digital ulcers remain one of the most devastating complications of systemic sclerosis-associated RP. They are associated with chronic pain, infection, impaired hand function, work disability, and reduced quality of life. Importantly, digital ulcers reflect progressive obliterative vasculopathy rather than isolated ischemic episodes. Their management therefore requires a multidisciplinary approach that extends beyond vasodilator therapy. Recent BSR guidelines appropriately recommend calcium channel blockers as first-line therapy for RP, with phosphodiesterase-5 inhibitors and intravenous prostanoids reserved for refractory disease [5]. Bosentan remains an important option for prevention of recurrent digital ulcers, while surgical sympathectomy and botulinum toxin injection may be considered in carefully selected patients with severe refractory ischemia. These recommendations reinforce the importance of individualized, stepwise treatment strategies rather than a one-size-fits-all approach. Perhaps the most important conceptual advance is the recognition that persistent or refractory digital ischemia should prompt clinicians to search for alternative pathogenic mechanisms. Not all digital ulcers result solely from vasospasm or structural vasculopathy. Superimposed inflammatory vasculitis, antiphospholipid syndrome, vaso-occlusive disease, calcinosis, or infection may significantly influence management decisions. Cases presented in recent educational sessions demonstrate that targeted immunosuppression or anticoagulation may be required when inflammatory or thrombotic mechanisms coexist. Such observations highlight the importance of individualized etiologic assessment before escalating vasodilator therapy alone. Future research should move beyond isolated biomarkers toward integrated digital vascular phenotyping. Combining capillaroscopic imaging, thermal imaging, patient-reported outcomes, laboratory biomarkers, wearable technologies, and artificial intelligence offers an opportunity to construct comprehensive digital vascular profiles. Such multidimensional assessment could facilitate earlier diagnosis, improve risk stratification, predict digital ulcer development, and guide personalized therapeutic interventions. In parallel, longitudinal observational studies are needed to determine how dynamic microvascular changes correlate with clinical outcomes and treatment response. The emergence of digital health technologies further expands these possibilities. Smartphone applications capable of capturing serial ulcer photographs or monitoring digital perfusion remotely may facilitate decentralized clinical trials and continuous patient monitoring. Integration of cloud-based image analysis with AI-assisted interpretation may allow community physicians to obtain expert-level support without requiring referral to specialized centers. These innovations align closely with the broader movement toward precision medicine and tele-rheumatology.

In conclusion, Raynaud's phenomenon should no longer be viewed simply as episodic vasospasm. Instead, it represents an accessible clinical model of systemic microvascular disease and an opportunity for early intervention before irreversible tissue injury occurs. Advances in capillaroscopy, artificial intelligence, patient-reported outcomes, and evidence-based therapeutic strategies are collectively reshaping the clinical management of RP and systemic sclerosis. The future lies not merely in treating vasospasm but in integrating multimodal vascular assessment with precision therapeutics to improve long-term outcomes. As these technologies become increasingly accessible, the transition from descriptive vascular assessment to quantitative precision microvascular medicine appears not only possible but inevitable.

Raynaud's phenomenon is an important clinical manifestation of systemic sclerosis-associated vascular disease, but its interpretation requires careful distinction between primary Raynaud's phenomenon, SSc-spectrum disease, and established systemic sclerosis. Nailfold capillaroscopy provides valuable objective information on microvascular structure and can contribute to the characterization and risk stratification of patients with suspected or established systemic sclerosis. However, capillaroscopic abnormalities should not be interpreted as a stand-alone predictor of individual clinical outcomes. Their prognostic significance is best considered in conjunction with clinical manifestations, disease characteristics, and SSc-specific autoantibodies. Patient-reported outcomes provide complementary information on symptom burden, functional impact, quality of life, and treatment response that cannot be fully captured by vascular imaging alone. Similarly, digital ulcers should be regarded as multifactorial vascular complications in which structural vasculopathy may coexist with vasospasm, thrombosis, calcinosis, trauma, infection, and other inflammatory or thrombotic mechanisms. Emerging technologies, including dermatoscopy, smartphone-based imaging, and artificial intelligence-assisted image analysis, may improve accessibility, quantitative assessment, longitudinal monitoring, and integration of microvascular data. Nevertheless, these approaches remain at different stages of validation. In particular, automated recognition of capillary abnormalities should be distinguished from prediction of clinically meaningful outcomes such as progression to systemic sclerosis, development of digital ulcers, or internal-organ involvement. Larger and more representative datasets, standardized image acquisition and scoring systems, external validation, and prospective studies demonstrating clinical utility are needed before these technologies can be incorporated routinely into clinical decision-making. The future of SSc-associated vascular assessment is therefore likely to involve complementary integration of clinical evaluation, nailfold imaging, patient-reported outcomes, serological characteristics, and emerging digital technologies. Rather than replacing established clinical assessment, these approaches may progressively enhance individualized risk assessment and longitudinal monitoring. A transition toward more quantitative and multimodal microvascular assessment is promising, but its clinical value should ultimately be determined by prospective validation and demonstrable improvements in patient care.

Chieh Chen: resources, data curation, writing – review and editing, visualization, supervision, project administration. Jeffrey Liao: data curation, writing – review and editing. Su-Boon Yong: resources, data curation, writing – review and editing, project administration. All authors have read and agreed to the final version of the manuscript. No generative artificial intelligence or artificial intelligence-assisted technology was used in the writing process, and the authors bear full responsibility for the content of their manuscripts.

The authors declare no conflicts of interest.

The data that support the findings of this study are available from the corresponding author upon reasonable request.